Fig. 3

Bevacizumab treatment decreases Aβ levels in the brains of 5×FAD mice. a Representative images of Aβ immunofluorescence staining and quantitative analyses of Aβ fluorescence intensity and % area in the hippocampus of female mice (n = 6–8 mice per group). Scale bar: 200 µm. b Representative images of Aβ immunofluorescence staining and quantitative analyses of Aβ fluorescence intensity and % area in the sensory cortex of female mice (n = 6–8 mice per group). Scale bar: 50 µm. c Representative images of Aβ immunofluorescence staining and quantitative analyses of Aβ fluorescence intensity and % area in the hippocampus of male mice (n = 6–7 mice per group). Scale bar: 200 µm. d Representative images of Aβ immunofluorescence staining and quantitative analyses of Aβ fluorescence intensity and % area in the sensory cortex of male mice (n = 6–7 mice per group). Scale bar: 50 µm. All data are presented as the mean ± SEM and were analyzed by unpaired two-tailed Student’s t test. WT (Veh): wild-type littermates receiving sham treatment, AD (Veh): 5×FAD mice receiving sham treatment, AD (Bev): 5×FAD mice receiving bevacizumab treatment